Stefan Endres

Stefan Endres

Auto-generated profile, based on publicly available information

Stefan Endres

Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2021 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
DBDaria Briukhovetska
Daria Briukhovetska
JDJanina Dörr
Janina Dörr
SEStefan Endres
Stefan Endres
PLPeter Libby
Peter Libby
CDCharles A. Dinarello
Charles A. Dinarello
SKSebastian Kobold
Sebastian Kobold

Verified
Journal Article
Open access
PDF file
MBMohamed-Reda Benmebarek
Mohamed-Reda Benmebarek
CKClara Helke Karches
Clara Helke Karches
BCBruno Cadilha
Bruno Cadilha
SLStefanie Lesch
Stefanie Lesch
SEStefan Endres
Stefan Endres
SKSebastian Kobold
Sebastian Kobold
Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen receptor (CAR) T cell therapy. CAR T cells mediate MHC-unrestricted tumor cell killing by enabling T cells to bind target cell surface antigens through a single-chain variable fragment (scFv) recognition domain. Upon engagement, CAR T cells form a non-classical immune synapse (IS), required for their effector function. These cells then mediate their anti-tumoral effects through the perforin and granzyme axis, the Fas and Fas ligand axis, as well as the release of cytokines to sensitize the tumor stroma. Their persistence in the host and functional outputs are tightly dependent on the receptor’s individual components—scFv, spacer domain, and costimulatory domains—and how said component functions converge to augment CAR T cell performance. In this review, we bring forth the successes and limitations of CAR T cell therapy. We delve further into the current understanding of how CAR T cells are designed to function, survive, and ultimately mediate their anti-tumoral effects.

19 June 2019 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SKStephan Kruger
Stephan Kruger
MIMatthias Ilmer
Matthias Ilmer
SKSebastian Kobold
Sebastian Kobold
BCBruno Cadilha
Bruno Cadilha
SEStefan Endres
Stefan Endres
MBMichael von Bergwelt-Baildon
Michael von Bergwelt-Baildon
Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with a broad variety of hematological and solid malignancies. The two main drivers behind this success are checkpoint inhibitors (CPIs) and chimeric antigen receptor (CAR) T cells. This review summarizes seminal findings from clinical and translational studies recently presented or published at important meetings or in top-tier journals, respectively. For checkpoint blockade, current studies focus on combinational approaches, perioperative use, new tumor entities, response prediction, toxicity management and use in special patient populations. Regarding cellular immunotherapy, recent studies confirmed safety and efficacy of CAR T cells in larger cohorts of patients with acute lymphoblastic leukemia or diffuse large B cell lymphoma. Different strategies to translate the striking success of CAR T cells in B cell malignancies to other hematological and solid cancer types are currently under clinical investigation. Regarding the regional distribution of registered clinical immunotherapy trials a shift from PD-1 / PD-L1 trials (mainly performed in the US and Europe) to CAR T cell trials (majority of trials performed in the US and China) can be noted.

25 March 2019 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MRMoritz Rapp
Moritz Rapp
MWMaximilian W.M. Wintergerst
Maximilian W.M. Wintergerst
WKWolfgang G. Kunz
Wolfgang G. Kunz
VVViola K. Vetter
Viola K. Vetter
MKMax M.L. Knott
Max M.L. Knott
DADavid Anz
David Anz
Chemokines have crucial roles in organ development and orchestration of leukocyte migration. The chemokine CCL22 is expressed constitutively at high levels in the lymph node, but the functional significance of this expression is so far unknown. Studying a newly established CCL22-deficient mouse, we demonstrate that CCL22 expression by dendritic cells (DCs) promotes the formation of cell–cell contacts and interaction with regulatory T cells (T reg) through their CCR4 receptor. Vaccination of CCL22-deficient mice led to excessive T cell responses that were also observed when wild-type mice were vaccinated using CCL22-deficient DCs. Tumor-bearing mice with CCL22 deficiency showed prolonged survival upon vaccination, and further, CCL22-deficient mice had increased susceptibility to inflammatory disease. In conclusion, we identify the CCL22–CCR4 axis as an immune checkpoint that is crucial for the control of T cell immunity.

3 June 2021 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
SLStefanie Lesch
Stefanie Lesch
VBViktoria Blumenberg
Viktoria Blumenberg
SSStefan Stoiber
Stefan Stoiber
AGAdrian Gottschlich
Adrian Gottschlich
JOJustyna Ogonek
Justyna Ogonek
SKSebastian Kobold
Sebastian Kobold

17 May 2019 in Cells
Verified
Journal Article
Open access
PDF file
SSstefan stoiber
stefan stoiber
BCBruno Cadilha
Bruno Cadilha
MBMohamed-Reda Benmebarek
Mohamed-Reda Benmebarek
SLStefanie Lesch
Stefanie Lesch
SEStefan Endres
Stefan Endres
SKSebastian Kobold
Sebastian Kobold
Cancer therapy has entered a new era, transitioning from unspecific chemotherapeutic agents to increasingly specific immune-based therapeutic strategies. Among these, chimeric antigen receptor (CAR) T cells have shown unparalleled therapeutic potential in treating refractory hematological malignancies. In contrast, solid tumors pose a much greater challenge to CAR T cell therapy, which has yet to be overcome. As this novel therapeutic modality matures, increasing effort is being invested to determine the optimal structure and properties of CARs to facilitate the transition from empirical testing to the rational design of CAR T cells. In this review, we highlight how individual CAR domains contribute to the success and failure of this promising treatment modality and provide an insight into the most notable advances in the field of CAR T cell engineering.